3D InSight ™ Drug-Induced Gastrointestinal Toxicity Assessment Schedule
Get robust, fast drug-induced gastrointestinal risk data with our standardized, automated phenotypic screening workflows. Book your service slot and receive a comprehensive report
3D InSight™ Drug-Induced Gastrointestinal Toxicity Assessment Schedule
Accelerate confident early decision-making with our standardized gastrointestinal cytotoxicity and organoid swelling assay for fast, reliable, and predictive assessment of drug-induced gastrointestinal toxicity (DIGIT) early in your drug discovery pipeline.
With our monthly expansion and seeding of patient-derived human intestinal organoids, you can efficiently streamline your DIGIT risk assessment while relying on a scalable, physiologically relevant 3D in vitro GI model.
DIGIT Service Schedule | Patient-derived Human Intestinal Organoid Model
The DIGIT™ assay includes a 2-day treatment period with multiplexed endpoints such as ATP, LDH, Live/Dead staining, and morphology analysis, providing robust insight into drug-induced gut cytotoxicity. The DIGIT Plus™ assay further expands this assessment by quantifying organoid swelling within the early treatment window, enabling functional evaluation of drug-induced fluid secretion liabilities.
Book your service slot and receive a comprehensive analysis report is delivered within 10 working days (DIGIT™) and 15 working days (DIGIT Plus™) after treatment, equipping you with actionable data to support clear go/no-go decisions.